IX Biopharma 42C

SGD 0.475 +0.00% +0.00 Updated 16 Nov 2026, 09:16 SGT

Company profile

The business, the people and the ownership behind IX Biopharma.

Business overview

About the company

iX Biopharma is a specialty pharmaceutical company focused on repurposing drugs using proprietary delivery technologies. Its WaferiX and WaferlogiX platforms support sublingual drug delivery and the development of new therapeutic uses or dosage forms.

Annual Report 2026 ↗ Reviewed 2026-10-23 · Source dated 2026-09-30. PDF p. 3

Listed security

Company & listing

Full Company Name
IX BIOPHARMA LTD.
Trading Currency
SGD
Website
www.ixbiopharma.com
Listing
Listed on 22 July 2015 on Catalist
ISIN Code
SG1BD9000009

Board & management

Leadership

Fourcurrentdirectors and threeadditional senior managers are disclosed. Chairman/CEOEddyLee duplicatedinSeniorManagement is consolidated into one rolefact. FormerexternalCFOroles ofTeoJohn are not listedCompanyCFO.

Initial appointment/lastre-electiondates and committee roles are printed in the original biographies and retained in source quotes; no report-year appointment date inferred.

Eddy Lee Yip Hang

Chairman & Chief Executive Officer

Board of iXBiopharmaLtd.; current report-date role

Patrick Donald Davies

Lead Independent Director

Board of iXBiopharmaLtd.; current report-date role

Teo Woon Keng John

Independent Non-Executive Director

Board of iXBiopharmaLtd.; current report-date role

Albert Ho Shing Tung

Non-Executive Director

Board of iXBiopharmaLtd.; current report-date role

Dr. Janakan Krishnarajah

Chief Operating Officer & Chief Medical Officer

Senior Management; Group pharmaceutical and nutraceutical development and AustralianGMPfacility

Eva Tan

Chief Commercial Officer

Senior Management; Groupglobalcommercialstrategies

Chew Sien Lup

Chief Financial Officer

Senior Management; Group accounting/financial/tax/investment matters

Roles listed in ANNUAL REPORT 2026; current appointments are not independently verified.

Holdings

Ownership

Two substantialholders and20listedlargestholders retain direct/deemed/nominee capacities. EddyLee spouse-deemed21,848,722 is separatefrom direct227,578,834; OCBCdeemed55,153,800 consists of BOSTL1,900,000 andLGI53,253,800 peroriginal footnotes; these are not extra nominee/additionalholdings.

Shareholderregisterdate11September2026 is laterthan financialpositiondate30June2026; registercapital$127,178,000/fullshares1,093,315,474 are not substituted for balance-datecapital$125,672thousand.

Originaltop20subtotal75.18%equals sumof20roundedholderpercentages, while821,885,822/1,093,315,474 rounds75.17%. Bothoriginal andseparate calculationretained; source doesnot state subtotalroundingmethod.

Eddy Lee Yip Hang

Direct interest 227,578,834 shares (20.82%); deemed interest 21,848,722 shares (2.00%).

Substantial shareholder direct/deemed interests,11September2026

Oversea-Chinese Banking Corporation Limited

Direct interest: – (–); deemed interest: 55,153,800 shares (5.04%).

Substantial shareholder direct/deemed interests,11September2026

Number of Shares in Issue

1,093,315,474 ordinary shares; Nil treasury shares; one vote per ordinary share; issued and fully paid-up capital $127,178,000

Original shareholder statistics as at11September2026

TOTAL

75.18%Total interest

821,885,822 shares
Original shareholder statistics as at11September2026

SHAREHOLDING HELD IN THE HANDS OF PUBLIC

70.72%

Original shareholder statistics as at11September2026

Total interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.

Registered & depository holders 20 holders

Registered holdings, including nominees and depositories; these do not establish ultimate beneficial ownership. As reported at 2026-09-11 · PDF p. 97

Registered holderInterestShares / unitsSource
EDDY LEE YIP HANG227,578,834 shares; 20.82% of shares.PDF p. 972026-09-11
CGS INTERNATIONAL SECURITIES SINGAPORE PTE. LTD.94,599,048 shares; 8.65% of shares.PDF p. 972026-09-11
PHILLIP SECURITIES PTE LTD84,635,938 shares; 7.74% of shares.PDF p. 972026-09-11
CITIBANK NOMINEES SINGAPORE PTE LTD81,478,856 shares; 7.45% of shares.PDF p. 972026-09-11
DBS NOMINEES PTE LTD50,756,409 shares; 4.64% of shares.PDF p. 972026-09-11
HSBC (SINGAPORE) NOMINEES PTE LTD47,994,161 shares; 4.39% of shares.PDF p. 972026-09-11
OCBC SECURITIES PRIVATE LTD42,985,950 shares; 3.93% of shares.PDF p. 972026-09-11
TANG CHOY LENG, JANE MRS JANE LEE CHOY LENG21,848,722 shares; 2.00% of shares.PDF p. 972026-09-11
MOOMOO FINANCIAL SINGAPORE PTE. LTD.21,537,083 shares; 1.97% of shares.PDF p. 972026-09-11
MAYBANK SECURITIES PTE. LTD.19,977,412 shares; 1.83% of shares.PDF p. 972026-09-11
WETWATERS 8 (S) PTE LTD16,650,270 shares; 1.52% of shares.PDF p. 972026-09-11
CHAN HWEE HOON15,487,234 shares; 1.42% of shares.PDF p. 972026-09-11
SEAH BOON LOCK15,045,869 shares; 1.38% of shares.PDF p. 972026-09-11
RAFFLES NOMINEES (PTE) LIMITED15,044,098 shares; 1.38% of shares.PDF p. 972026-09-11
ALBERT HO SHING TUNG13,200,219 shares; 1.21% of shares.PDF p. 972026-09-11
SNG BENG HOCK MICHAEL12,825,000 shares; 1.17% of shares.PDF p. 972026-09-11
MERRILL LYNCH (SINGAPORE) PTE LTD11,866,600 shares; 1.09% of shares.PDF p. 972026-09-11
HARDEEP KAUR D/O HARDIAL SINGH11,518,639 shares; 1.05% of shares.PDF p. 972026-09-11
JASVINPAL SINGH NARULLA8,648,700 shares; 0.79% of shares.PDF p. 972026-09-11
ABN AMRO CLEARING BANK N.V.8,206,780 shares; 0.75% of shares.PDF p. 972026-09-11

Group structure

Main operating subsidiaries

Twelve subsidiaries with full activities,country/businessincorporation and explicit parentpaths: sevenheldbyCompany, threebyEntityHealthLtd, onebyEntityHealth(China)CompanyLtd andonebyiXBiopharmaEuropeLimited. Original2026/2025immediate-holder equityholding is100/100 for each; no undisclosed effectivepercentage is inferred.

Original audits: (a)BDO LLP forGroupfinancials without statutoryaudits required locally;(b)BDO LLP forGroupfinancials;(c)S.Y.Wong;(d)LigoPharma dormant;(e)BDO LLP Singapore;(f)ShenzhenPengrun;(g)Cleary&CompanyIreland. Sourcefootnotemarkers/full originalnotes retained.

CompanyMarketOwnership interest
iX Biopharma Pty LtdSubsidiary; held by Company; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred Country: Australia; activities: Research and experimental development; 100%; 100%
iX Syrinx Pty Ltd (“Syrinx”)Subsidiary; held by Company; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred Country: Australia; activities: Manufacturing and sale of pharmaceutical and nutraceutical products; 100%; 100%
Arrow Property TrustSubsidiary; held by Company; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred Country: Australia; activities: Owner of an industrial property that is leased exclusively to Syrinx; 100%; 100%
Kaizen Manufacturing Pty LtdSubsidiary; held by Company; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred Country: Australia; activities: Trustee of Arrow Property Trust; 100%; 100%
Entity Health LtdSubsidiary; held by Company; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred Country: Hong Kong; activities: Promotion and marketing of nutraceutical products; 100%; 100%
iX Biopharma Europe LimitedSubsidiary; held by Company; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred Country: Ireland; activities: Promotion and marketing of pharmaceutical and nutraceutical products; 100%; 100%
Ligo Pharma LimitedSubsidiary; held by Company; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred Country: Cayman Islands; activities: Investment holding company; 100%; 100%
Entity Health Pte LtdSubsidiary; held by Entity Health Ltd; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred Country: Singapore; activities: Promotion and marketing of nutraceutical products; 100%; 100%
Entity Health (China) Company LtdSubsidiary; held by Entity Health Ltd; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred Country: Hong Kong; activities: Investment holding company; 100%; 100%
Entity Health Pty LtdSubsidiary; held by Entity Health Ltd; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred Country: Australia; activities: Promotion and marketing of nutraceutical products; 100%; 100%
Entity Health (Shanghai) Co LtdSubsidiary; held by Entity Health (China) Company Ltd; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred Country: China; activities: Promotion and marketing of nutraceutical products; 100%; 100%
Entity Health, Inc.Subsidiary; held by iX Biopharma Europe Limited; original immediate-holder equityholding2026then2025; no separately disclosed Group effective interest inferred Country: United States of America; activities: Promotion and marketing of pharmaceutical and nutraceutical products; 100%; 100%

Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.

Senior executives

Key management

Key management

ItemValuePeriod / scopeSource
Eddy Lee Yip Hang Chairman & Chief Executive Officer Senior Management PDF p. 27
Dr. Janakan Krishnarajah Chief Operating Officer & Chief Medical Officer Senior Management PDF p. 27
Eva Tan Chief Commercial Officer Senior Management PDF p. 27
Chew Sien Lup Chief Financial Officer Senior Management PDF p. 27
Jeremy Dalton General Manager Senior Management PDF p. 28
Dr. Iain Cook Chief Scientist Senior Management PDF p. 28
Dr. Stephen Lim Chief Pharmacist Senior Management PDF p. 28

Extracted from ANNUAL REPORT 2026 and checked against the cited pages; see the original report for full context.

Shareholding statistics

Share capital & shareholders

Share capital

ItemValuePeriod / scopeSource
Issued and Fully Paid-Up Capital $127,178,000 Company · As at 2026-09-11 PDF p. 97
Number of Shares in Issue 1,093,315,474 shares Company · As at 2026-09-11 PDF p. 97
Class of Share Ordinary Shares Company · As at 2026-09-11 PDF p. 97
Voting Rights One vote per Ordinary Share Company · As at 2026-09-11 PDF p. 97

Treasury shares

ItemValuePeriod / scopeSource
Treasury Shares Nil Company · As at 2026-09-11 PDF p. 97

Shareholding distribution

ItemValuePeriod / scopeSource
TOTAL 1,993 shareholders Company, all size bands; shareholders 100.00%, shares 1,093,315,474 (100.00%) · As at 2026-09-11 PDF p. 97
1 - 99 43 holders; 2.16% of holders; 2,113 shares; 0.00% of shares Size band 1-99 · As at 2026-09-11 PDF p. 97
100 - 1,000 106 holders; 5.32% of holders; 65,902 shares; 0.01% of shares Size band 100-1,000 · As at 2026-09-11 PDF p. 97
1,001 - 10,000 535 holders; 26.84% of holders; 3,605,601 shares; 0.33% of shares Size band 1,001-10,000 · As at 2026-09-11 PDF p. 97
10,001 - 1,000,000 1,237 holders; 62.07% of holders; 121,571,313 shares; 11.12% of shares Size band 10,001-1,000,000 · As at 2026-09-11 PDF p. 97
1,000,001 AND ABOVE 72 holders; 3.61% of holders; 968,070,545 shares; 88.54% of shares Size band 1,000,001 and above · As at 2026-09-11 PDF p. 97

Free float

ItemValuePeriod / scopeSource
Shareholding held in the hands of public approximately 70.72% of the shareholdings of the Company is held in the hands of the public and therefore Rule 723 of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited has been complied with Company · As at 2026-09-11 PDF p. 98

Extracted from ANNUAL REPORT 2026 and checked against the cited pages; see the original report for full context.

Related parties, people & properties

Other disclosures

Related party transactions

ItemValuePeriod / scopeSource
Fee related to licensing to subsidiaries 287 $'000 Company transactions with subsidiaries, FY2026 (comparative 2025: 295) PDF p. 93
Purchases of inventories from subsidiaries 96 $'000 Company transactions with subsidiaries, FY2026 (comparative 2025: 12) PDF p. 93
Professional fee recharged to subsidiaries 166 $'000 Company transactions with subsidiaries, FY2026 (comparative 2025: 138) PDF p. 93
Key management personnel compensation (total) 4,372 $'000 Group and Company, 2026 (comparative 2025: 2,216) PDF p. 93

Contingent liabilities

ItemValuePeriod / scopeSource
Capital commitments $73,000 Group, at balance sheet date 30 June 2026 (2025: $3,000) PDF p. 86

Director remuneration

ItemValuePeriod / scopeSource
Eddy Lee Yip Hang $1,965.3 FY2026, $'000 total; Fees – ; Fixed Salary 19%; Bonus 5%; Other Benefits 50%; Share-based 26% PDF p. 36
Albert Ho Shing Tung $83.5 FY2026, $'000 total; Fees 100% PDF p. 36
Patrick Donald Davies $89.5 FY2026, $'000 total; Fees 100% PDF p. 36
Teo Woon Keng John $83.5 FY2026, $'000 total; Fees 100% PDF p. 36

Subsequent events

ItemValuePeriod / scopeSource
Emergency Use Authorization Declaration 3 September 2026, the US Government published an After the close of FY2026 PDF p. 9

Outlook

ItemValuePeriod / scopeSource
Chairman's closing statement Our singular focus now is execution. Chairman & CEO statement, FY2026 PDF p. 9

Extracted from ANNUAL REPORT 2026 and checked against the cited pages; see the original report for full context.

Source: ANNUAL REPORT 2026 ↗

Corporate information

Registration & contacts

Incorporated In
SINGAPORE
Incorporated On
08 May 2004
Telephone
65 62352270
Fax
65 62352170
Registered Office
20 Collyer Quay
#11-07
Singapore 049319
Secretary
Lai Kuan Loong Victor
Lee Soo Fern Gwendolin
Registrar / Transfer Agent
TRICOR BARBINDER SHARE REGISTRATION SERVICES
Registrar Address
9 Raffles Place, Republic Plaza Tower I #26-01, Singapore 048619
Auditors
BDO LLP
Other Stock Exchange Listings
*SINGAPORE EXCHANGE (CATALIST)
Country
SINGAPORE
Security Type
stocks